trans-(+/-)-3,5-dimethylpiperidine | 32452-46-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: trans-(+/-)-3,5-dimethylpiperidine
• 英文别名: trans-3,5-dimethylpiperidine；(3S,5S)-3,5-dimethylpiperidine
• CAS: 32452-46-3
• 化学式: C₇H₁₅N
• 分子量: 113.203
• InChiKey: IDWRJRPUIXRFRX-BQBZGAKWSA-N

物化性质

• 沸点：
  141.2±8.0 °C(Predicted)
• 密度：
  0.794±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  trans-(+/-)-3,5-dimethylpiperidine 在 氨 、 氢气 、 formamide 作用下， 以 甲醇 、 水 为溶剂， 20.0 ℃ 、1.52 MPa 条件下， 反应 31.0h， 生成 (±)-3-(trans-3,5-dimethylpiperidin-1-yl)propan-1-amine
  参考文献：
  名称：

  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

  摘要：

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

  DOI：

  10.1021/acs.jmedchem.7b00561
• 作为产物：
  描述：

  (2S,4S)-2,4-dimethylpentanedinitrile 在 5% Rh/Al2O3 氢气 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 trans-(+/-)-3,5-dimethylpiperidine
  参考文献：
  名称：

  Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands

  摘要：

  本专利申请涉及公式（I）的化合物，其中R1和R2与它们所连接的氮原子一起形成一个单环或双环饱和氮含环；它们的制备以及它们作为H3受体配体用于治疗例如阿尔茨海默病等中枢神经系统疾病。

  公开号：

  EP1717234A1

文献信息

• [EN] NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 6-AMINO-QUINOLINONE ET DÉRIVÉS EN TANT QU'INHIBITEURS DE BCL6
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018108704A1

  公开（公告）日：2018-06-21

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式(I)的化合物，其中基团R1至R5、X、Y和W具有权利要求和说明中给定的含义，它们作为BCL6的抑制剂的用途，含有这种化合物的药物组合物以及它们作为药物的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• [EN] 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE SUBSTITUES EN POSITION 4
  申请人：BIOAXONE THERAPEUTIQUE INC

  公开号：WO2005080394A1

  公开（公告）日：2005-09-01

  Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构I表示的取代哌啶化合物，其中Rla、R1b、R1c、R1d、Rle、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n中的每一个如规范中定义。结构I的取代哌啶化合物可能渗透或穿过神经细胞膜进入神经细胞内部，可能抑制哺乳动物神经细胞中的细胞内Rho激酶酶，并可能在这些哺乳动物的中枢和外周神经系统中修复受损神经时发挥作用。这些化合物可能诱导哺乳动物神经细胞中神经突起的再生或生长，从而诱导受损或患病神经组织的再生。这些化合物还可作为Rho激酶酶拮抗剂在治疗涉及Rho激酶的疾病状态中发挥额外作用。含有这些取代哌啶化合物的药物组合物可能有助于促进神经突起的生长，并在需要Rho激酶抑制的疾病治疗中发挥作用。
• Coupling process for preparing quinolone intermediates
  申请人：Reilly Michael

  公开号：US20070232804A1

  公开（公告）日：2007-10-04

  Process for making 7-cycloamino-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids. Borate ester compounds suitable for use in such process.

  制备7-环氨基-1-环丙基-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸的过程。适用于该过程的硼酸酯化合物。
• [EN] TRICYCLIC PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PIPÉRIDINIQUES TRICYCLIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015075023A1

  公开（公告）日：2015-05-28

  The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及公式（I）的化合物，其中R、R1a、R1b、R2、R3和X如描述中所述，以及它们的制备方法，其药用盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，以及制备这种公式（I）化合物的方法，特别是它们作为TPH调节剂的用途。
• [EN] STRUCTURE DIRECTING AGENT FOR IMPROVED SYNTHESIS OF ZEOLITES<br/>[FR] AGENT DIRECTEUR DE STRUCTURE POUR SYNTHÈSE DE ZÉOLITES AMÉLIORÉE.
  申请人：SACHEM INC

  公开号：WO2016149234A1

  公开（公告）日：2016-09-22

  The present invention relates to structure directing agents for synthesis of crystalline materials generally known as zeolites, by use of an enhanced content of the trans isomer of a 3,5-dimethyl-N,N-dimethylpiperidinium cation together with the conventional oxides used to form zeolites.

  本发明涉及结构定向剂，用于合成晶体材料，通常被称为沸石，通过使用增强的3,5-二甲基-N，N-二甲基哌啶阳离子的反式异构体的含量以及用于形成沸石的传统氧化物。